| pubmed-article:18950459 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18950459 | lifeskim:mentions | umls-concept:C0079731 | lld:lifeskim |
| pubmed-article:18950459 | lifeskim:mentions | umls-concept:C0393022 | lld:lifeskim |
| pubmed-article:18950459 | lifeskim:mentions | umls-concept:C0184511 | lld:lifeskim |
| pubmed-article:18950459 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:18950459 | lifeskim:mentions | umls-concept:C0332256 | lld:lifeskim |
| pubmed-article:18950459 | lifeskim:mentions | umls-concept:C1514832 | lld:lifeskim |
| pubmed-article:18950459 | lifeskim:mentions | umls-concept:C0522501 | lld:lifeskim |
| pubmed-article:18950459 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:18950459 | pubmed:dateCreated | 2008-11-27 | lld:pubmed |
| pubmed-article:18950459 | pubmed:abstractText | Many controlled clinical trials have proven that rituximab improves the clinical outcome of patients with mature B cell lymphoma. This study was conducted to assess the contribution of rituximab in the actual clinical practice. Patients with newly diagnosed mature B cell lymphoma treated at 20 National Hospital Organization hospitals from January 2000 to December 2004 were consecutively registered. Rituximab was approved in September 2002 for indolent B cell lymphoma and in September 2003 for aggressive B cell lymphoma in Japan. The patients were divided into two groups depending on whether they received induction therapy containing rituximab. The endpoint was to evaluate the rituximab benefit based on 2-year progression-free survival (PFS) and 2-year overall survival (OS). A total 1126 patients received chemotherapies. Of these, 762 were diagnosed as diffuse large B cell lymphoma (DLBCL) and 215 as follicular lymphoma (FL). PFS and OS were markedly improved in the rituximab group compared with the non-rituximab group in patients with DLBCL (both P < 0.001) and in patients with FL (P < 0.001 and P = 0.003 respectively). Rituximab, when used for remission induction therapy, significantly improved the clinical outcome of the mature B cell lymphoma patient in actual clinical practice. | lld:pubmed |
| pubmed-article:18950459 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18950459 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18950459 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18950459 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18950459 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18950459 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18950459 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18950459 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:18950459 | pubmed:issn | 1365-2141 | lld:pubmed |
| pubmed-article:18950459 | pubmed:author | pubmed-author:YanoTakahiroT | lld:pubmed |
| pubmed-article:18950459 | pubmed:author | pubmed-author:HottaTomomits... | lld:pubmed |
| pubmed-article:18950459 | pubmed:author | pubmed-author:WatanabeTomoy... | lld:pubmed |
| pubmed-article:18950459 | pubmed:author | pubmed-author:OkamuraSeiich... | lld:pubmed |
| pubmed-article:18950459 | pubmed:author | pubmed-author:NishiuraTetsu... | lld:pubmed |
| pubmed-article:18950459 | pubmed:author | pubmed-author:HoribeKeizoK | lld:pubmed |
| pubmed-article:18950459 | pubmed:author | pubmed-author:UikeNaokuniN | lld:pubmed |
| pubmed-article:18950459 | pubmed:author | pubmed-author:InoueNobumasa... | lld:pubmed |
| pubmed-article:18950459 | pubmed:author | pubmed-author:KawanoFumioF | lld:pubmed |
| pubmed-article:18950459 | pubmed:author | pubmed-author:HanadaShuichi... | lld:pubmed |
| pubmed-article:18950459 | pubmed:author | pubmed-author:NagaiHirokazu... | lld:pubmed |
| pubmed-article:18950459 | pubmed:author | pubmed-author:SunamiKazutak... | lld:pubmed |
| pubmed-article:18950459 | pubmed:author | pubmed-author:SawamuraMorio... | lld:pubmed |
| pubmed-article:18950459 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18950459 | pubmed:volume | 143 | lld:pubmed |
| pubmed-article:18950459 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18950459 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18950459 | pubmed:pagination | 672-80 | lld:pubmed |
| pubmed-article:18950459 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:18950459 | pubmed:meshHeading | pubmed-meshheading:18950459... | lld:pubmed |
| pubmed-article:18950459 | pubmed:meshHeading | pubmed-meshheading:18950459... | lld:pubmed |
| pubmed-article:18950459 | pubmed:meshHeading | pubmed-meshheading:18950459... | lld:pubmed |
| pubmed-article:18950459 | pubmed:meshHeading | pubmed-meshheading:18950459... | lld:pubmed |
| pubmed-article:18950459 | pubmed:meshHeading | pubmed-meshheading:18950459... | lld:pubmed |
| pubmed-article:18950459 | pubmed:meshHeading | pubmed-meshheading:18950459... | lld:pubmed |
| pubmed-article:18950459 | pubmed:meshHeading | pubmed-meshheading:18950459... | lld:pubmed |
| pubmed-article:18950459 | pubmed:meshHeading | pubmed-meshheading:18950459... | lld:pubmed |
| pubmed-article:18950459 | pubmed:meshHeading | pubmed-meshheading:18950459... | lld:pubmed |
| pubmed-article:18950459 | pubmed:meshHeading | pubmed-meshheading:18950459... | lld:pubmed |
| pubmed-article:18950459 | pubmed:meshHeading | pubmed-meshheading:18950459... | lld:pubmed |
| pubmed-article:18950459 | pubmed:meshHeading | pubmed-meshheading:18950459... | lld:pubmed |
| pubmed-article:18950459 | pubmed:meshHeading | pubmed-meshheading:18950459... | lld:pubmed |
| pubmed-article:18950459 | pubmed:meshHeading | pubmed-meshheading:18950459... | lld:pubmed |
| pubmed-article:18950459 | pubmed:meshHeading | pubmed-meshheading:18950459... | lld:pubmed |
| pubmed-article:18950459 | pubmed:meshHeading | pubmed-meshheading:18950459... | lld:pubmed |
| pubmed-article:18950459 | pubmed:meshHeading | pubmed-meshheading:18950459... | lld:pubmed |
| pubmed-article:18950459 | pubmed:meshHeading | pubmed-meshheading:18950459... | lld:pubmed |
| pubmed-article:18950459 | pubmed:meshHeading | pubmed-meshheading:18950459... | lld:pubmed |
| pubmed-article:18950459 | pubmed:meshHeading | pubmed-meshheading:18950459... | lld:pubmed |
| pubmed-article:18950459 | pubmed:meshHeading | pubmed-meshheading:18950459... | lld:pubmed |
| pubmed-article:18950459 | pubmed:meshHeading | pubmed-meshheading:18950459... | lld:pubmed |
| pubmed-article:18950459 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18950459 | pubmed:articleTitle | Remission induction therapy containing rituximab markedly improved the outcome of untreated mature B cell lymphoma. | lld:pubmed |
| pubmed-article:18950459 | pubmed:affiliation | Clinical Research Centre, National Hospital Organization Nagoya Medical Centre, Nagoya, Japan. nagaih@nnh.hosp.go.jp | lld:pubmed |
| pubmed-article:18950459 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18950459 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:18950459 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
